TRAVERE THERAPEUTICS INC (TVTX) Stock Price, Quote, News and Overview
NASDAQ:TVTX - Nasdaq - US89422G1076 - Common Stock - Currency: USD
TVTX Quote, Performance and Key Statistics
TRAVERE THERAPEUTICS INC
NASDAQ:TVTX (1/27/2025, 11:18:09 AM)
20.44
+0.13 (+0.64%)
The current stock price of TVTX is 20.44 USD. In the past month the price increased by 18.43%. In the past year, price increased by 136.16%.
TVTX Latest News, Press Releases and Analysis
Travere Therapeutics Provides Corporate Update and 2025 Outlook
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief...
Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the...
TVTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.21 | 307.91B | ||
| AMGN | AMGEN INC | 14.48 | 149.63B | ||
| GILD | GILEAD SCIENCES INC | 21.44 | 118.37B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 861.86 | 113.20B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.04 | 75.06B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 36.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.09B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.16B | ||
| NTRA | NATERA INC | N/A | 22.10B | ||
| BIIB | BIOGEN INC | 9.1 | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.26B |
Related stock screener links
About TVTX
Company Profile
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 380 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
Company Info
TRAVERE THERAPEUTICS INC
3611 Valley Centre Dr, Suite 300
San Diego CALIFORNIA 92130 US
CEO: Eric M. Dube
Employees: 380
Company Website: https://travere.com/
Investor Relations: https://ir.travere.com/
Phone: 18889697879
TVTX FAQ
What is the stock price of TVTX?
The current stock price of TVTX is 20.44 USD.
What is the symbol for TRAVERE THERAPEUTICS INC stock?
The exchange symbol of TRAVERE THERAPEUTICS INC is TVTX and it is listed on the Nasdaq exchange.
On which exchange is TVTX stock listed?
TVTX stock is listed on the Nasdaq exchange.
Is TVTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for TVTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of TVTX.
Does TVTX stock pay dividends?
TVTX does not pay a dividend.
When does TVTX stock report earnings?
TVTX will report earnings on 2025-02-13, after the market close.
What is the Price/Earnings (PE) ratio of TVTX?
TVTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.4).
What is the Short Interest ratio of TVTX stock?
The outstanding short interest for TVTX is 10.31% of its float.
TVTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TVTX. When comparing the yearly performance of all stocks, TVTX is one of the better performing stocks in the market, outperforming 95.12% of all stocks.
TVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TVTX. Both the profitability and financial health of TVTX have multiple concerns.
TVTX Financial Highlights
Over the last trailing twelve months TVTX reported a non-GAAP Earnings per Share(EPS) of -4.4. The EPS increased by 4.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.68% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TVTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to TVTX. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 16.7% and a revenue growth 18.73% for TVTX